CN105362417A - 一种橄榄油复方保健喷雾剂及制备方法 - Google Patents
一种橄榄油复方保健喷雾剂及制备方法 Download PDFInfo
- Publication number
- CN105362417A CN105362417A CN201510776585.0A CN201510776585A CN105362417A CN 105362417 A CN105362417 A CN 105362417A CN 201510776585 A CN201510776585 A CN 201510776585A CN 105362417 A CN105362417 A CN 105362417A
- Authority
- CN
- China
- Prior art keywords
- olive oil
- oil
- preparation
- compound health
- spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008390 olive oil Nutrition 0.000 title claims abstract description 24
- 239000004006 olive oil Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 239000007921 spray Substances 0.000 title claims abstract description 13
- 230000036541 health Effects 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 30
- 239000003921 oil Substances 0.000 claims abstract description 21
- 235000019198 oils Nutrition 0.000 claims abstract description 21
- 241000241413 Propolis Species 0.000 claims abstract description 13
- 229940069949 propolis Drugs 0.000 claims abstract description 13
- 244000131360 Morinda citrifolia Species 0.000 claims abstract description 11
- 235000017524 noni Nutrition 0.000 claims abstract description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 229940041678 oral spray Drugs 0.000 claims description 10
- 239000000668 oral spray Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 206010012335 Dependence Diseases 0.000 abstract 1
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 235000008898 Morinda citrifolia Nutrition 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 24
- 239000000284 extract Substances 0.000 description 20
- 206010016256 fatigue Diseases 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- -1 chromocor compound Chemical class 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明所述的一种橄榄油复方保健喷雾剂及制备方法，橄榄油、蜂胶、红景天油、诺丽籽油为纯天然药食同源材料，利用它们的协同作用，所选药物均为天然植物药物，各药之间配伍科学,具有明显的协同作用,制备工艺合理,不破坏中药原料的有效成分,无毒副作用,无成瘾性,无耐药性，对各种疼痛，尤其是缓解疲劳效果明显，可制成适合使用剂型,适合人们作为保健品在日常生活中服用，具有很好的市场前景。
Description
技术领域
本发明提供一种橄榄油复方保健喷雾剂及制备方法，对抗疲劳具有明显的医疗作用，属于保健食品技术领域。
背景技术
目前，随着社会经济的迅速发展、工业现代化程度的提高，人们的生活节奏明显加快。工业化程度的提高必然会带来诸如空气和水源污染加剧、生存环境恶化等负面影响，疲劳是一种生理范畴的全身性反应，主要表现为劳累不适感和工作能力的降低，一般来说，人体的各种生理活动都有一定的限度，一旦超过限度，大脑就会发出种种疲劳信号，通过休息、睡眠等必要措施，便可减轻或消除疲劳，从而避免成疾。在人类生活中，疲劳并非完全是由于体力劳动和体育运动等身体过于劳累引起的，随着现代工作和身体条件的改善，人们体力上的劳累已经不适疲劳的主要原因，由于生活节奏的加快和时间效率观念的增强，现代人更多的是脑力疲劳，心理疲劳和病态疲劳,总之，大量亚健康人群随之出现，疲劳已成为全球关注的严重问题。
发明内容
本发明提供一种橄榄油复方保健喷雾剂，对抗疲劳具有明显的医疗作用。
本发明还公开了一种橄榄油复方保健喷雾剂的制备方法，工艺简单、容易操作,生产成本低廉，适用于工业化生产。
本发明所述的一种橄榄油复方保健喷雾剂，其特征在于是由以下药物按重量份数比制成的：
橄榄油25~45、蜂胶10~25、红景天油10~25、诺丽籽油10~25。
本发明所述的一种橄榄油复方保健喷雾剂的制备方法，包括以下步骤：
按比例称取上述原料；橄榄油、红景天油、诺丽籽油混合调配成调和油后，再与蜂胶制成油相混合物，再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂，即得。
【用法用量】口服；2次/日；10~15ml/次。
【适应症】抗疲劳；适应于亚健康，血糖、血脂、血压三高人群，免疫力低下。易疲劳、易失眠；性欲低感觉差；体质弱；腰膝乏力；经常健忘；更年期综合症及亚健康人群。
本发明的保健作用分析：
橄榄油：净化血液，软化血管，保肝护肝，促进B细胞分泌胰岛素；活血化瘀，抗炎生肌，心脑血管的保护神，防止人体血清胆固醇在血管壁里沉积，防治动脉粥样硬化及心血管疾病的医疗保健效果。沙棘黄酮可以通过清除活性氧自由基起到抗心律失常、抗心肌缺血、缩小心肌梗塞面积、缓解心绞痛、改善心功能的作用。
蜂胶：含有黄酮化合物包括黄酮类、黄酮醇类和双氢黄酮类等，约占蜂胶的4.13%，具有多方面的生理和药理作用，能帮助人体防治多种疾病，使机体各种功能正常化、增强化。蜂胶中的黄酮类化合物，其品种之多、含量之高超过了一般的植物药。对治疗冠心病有效的许多中草药都含有黄酮类化合物。
红景天油：除了主要药效成分红景天苷和酪醇外，还含有丰富的其他苷类化合物、氨基酸、微量元素、挥发油、多糖等成分。药理研究证明其具有免疫调节、抗病毒、抗缺氧、降血糖、神经细胞保护、肝脏保护、益智、抗氧化、防辐射等多种药理学作用。
诺丽籽油：内含黄酮、有机酸、生物碱、甾醇类、三萜烯类及各种维生素等140多种生物活性成分。具有消炎止痛、按摩消解疲劳功能；协助溶解胆固醇。抗敏感、提亮肤色、晒后修复、活肤滋润、抗衰老。
本发明以橄榄油为主，稳定安全，对抗疲劳具有明显的医疗作用，加入红景天油、诺丽籽油和蜂胶协同配伍增强了这种功效，且使脂肪酸比例符合营养学标准，防止某些由于油脂摄入不平衡引起的慢性病，可降低动脉硬化的发生。上述各药相互作用，可以补气补血，延缓衰老；可显著提高机体器官功能，快速恢复体力和精力，抗疲劳，适应于亚健康，血糖、血脂、血压三高人群，免疫力低下。通过舌下粘膜直接吸收入血液，服用方便，避免被胃酸的分解破坏，也不会被肝脏酶的代谢，保持药效同时也减轻了药物对胃肠道和肝脏的毒副作用,平均生物利用度较高，不良反应较小，有较好的依从性。
本发明的积极效果在于：橄榄油、蜂胶、红景天油、诺丽籽油为纯天然药食同源材料，利用它们的协同作用，所选药物均为天然植物药物，各药之间配伍科学,具有明显的协同作用,制备工艺合理,不破坏中药原料的有效成分,无毒副作用,无成瘾性,无耐药性，对各种疼痛，尤其是缓解疲劳效果明显，可制成适合使用剂型,适合人们作为保健品在日常生活中服用，具有很好的市场前景。
具体实施方式
通过以下实施例进一步举例描述本发明，并不以任何方式限制本发明，在不背离本发明的技术解决方案的前提下，对本发明所作的本领域普通技术人员容易实现的任何改动或改变都将落入本发明的权利要求范围之内。
实施例1
称取橄榄油25g、红景天油10g、诺丽籽油10g混合调配成调和油后，再与蜂胶10g制成油相混合物，再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂，即得。
实施例2
称取橄榄油35g、红景天油15g、诺丽籽油15g混合调配成调和油后，再与15g蜂胶制成油相混合物，再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂，即得。
实施例3
称取橄榄油45g、红景天油25g、诺丽籽油25g混合调配成调和油后，再与蜂胶25制成油相混合物，再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂，即得。
通过以下典型动物实验进一步表明本发明药物的治疗效果：
按照实施例1~实施例3中提供的方法制备得到的中药复方提取物，进行了药效学实验，研究结果如下：
1．小鼠疲劳转棒实验
将实施例1~实施例3制备的中药组合提取物用去离子水，乙醇和吐温80(v/v/v=95/3/2)混合溶液配置成高中低三个剂量组，取40只昆明小鼠，体重18-22g，雌雄各半，随机分成4组，每组10只，分别为空白组，中药组合提取物组（实施例1实施例2实施例3），各组以0.1ml/10g的水平进行灌胃，剂量分别为2、5和10g/kg，空白对照组以0.1ml/10g的生理盐水灌胃，每日一次，连续7天。每组小鼠分别放在转棒上，使肌肉处在静力紧张的状态。调节转棒的速度为20rpm/min,记录各组小鼠由于肌肉疲劳从玻璃棒上跌下的时间，实验前训练2次，第3次开始计时，跌落时终止实验，第3次的时间作为小鼠爬杆时间，并记录。结果见表1。
表1不同剂量中药组合提取物对小鼠在疲劳转棒试验的影响
| 组别 | 停留时间（s） |
| 空白组 | 36.27±10.15 |
| 实施例1 | 70.89±9.28* |
| 实施例2 | 72.47±11.48** |
| 实施例3 | 74.56±12.38** |
*与空白组比P＜0.05，**与空白组比＜0.01
由表1可见，中药组合提取物（实施例1实施例2实施例3）组小鼠在转棒上的停留时间与空白组相比有显著性的差异，这说明中药组合提取物能够延长小鼠疲劳时间，即说明具有抗疲劳作用。
2.小鼠耐力跑实验
将实施例1~实施例3制备的中药组合提取物用去离子水，乙醇和吐温80(v/v/v=95/3/2)混合溶液配置成高中低三个剂量组，取40只昆明小鼠，体重18-22g，雌雄各半，随机分成4组，每组10只，分别为空白组，中药组合提取物组（实施例1实施例2实施例3），各组以0.1ml/10g的水平进行灌胃，剂量分别为2、5和10g/kg，空白对照组以0.1ml/10g的生理盐水灌胃，每日一次，连续7天。末次给药1小时后，每组小鼠分别放在小鼠跑步机上，先放置好动物，对小鼠进行训练1min，使其了解逃离带电区域后，将转速设为20rpm，电流调到30A，记录各剂量组4min内小鼠被电击的次数。结果见表2。
表2不同剂量中药组合提取物对小鼠电击次数的影响
| 组别 | 电击次数（n） |
| 空白组 | 53.47±3.57 |
| 实施例1 | 47.00±1.97 |
| 实施例2 | 36.55±4.06** |
| 实施例3 | 38.29±3.69** |
*与空白组比P＜0.05，**与空白组比＜0.01
由表2可见，实施例1实施例2实施例3与空白组对比有显著性差异，实施例3组与空白组对比有及其显著性差异，综合来看，中药组合提取物对小鼠耐抗疲劳能力产生影响。
3.小鼠负重游泳实验
将实施例1~实施例3制备的中药组合提取物用去离子水，乙醇和吐温80(v/v/v=95/3/2)混合溶液配置成高中低三个剂量组，取40只昆明小鼠，体重18-22g，雌雄各半，随机分成4组，每组10只，分别为空白组，中药组合提取物组（实施例1实施例2实施例3），各组以0.1ml/10g的水平进行灌胃，剂量分别为2、5和10g/kg，空白对照组以0.1ml/10g的生理盐水灌胃，每日一次，连续7天。末次给药1小时后，在小鼠尾部绑与铅粒（铅粒与小鼠体重的重量比1:10）依次将各剂量组与空白组小鼠置于负重游泳测试仪中，水深25cm，水温25±2℃，测定各组小鼠游泳力竭的时间，并记录。结果见表3。
表3不同剂量中药组合提取物对小鼠负重游泳的影响
| 组别 | 力竭时间（s） |
| 空白组 | 204.17±20.76 |
| 实施例1 | 310.64±18.61* |
| 实施例2 | 332.15±22.69** |
| 实施例3 | 345.73±27.39** |
*与空白组比P＜0.05，**与空白组比＜0.01
由表3可见，实施例1实施例2实施例3与空白组对比有显著性差异，实施例3组与空白组对比有及其显著性差异，综合来看，中药组合提取物对小鼠耐抗疲劳能力产生影响。
4.小鼠常压缺氧耐受实验
将实施例1~实施例3制备的中药组合提取物用去离子水，乙醇和吐温80(v/v/v=95/3/2)混合溶液配置成组（实施例1实施例2实施例3），取40只昆明小鼠，体重18-22g，雌雄各半，随机分成4组，每组10只，分别为空白组，中药组合提取物组（实施例1实施例2实施例3），各组以0.1ml/10g的水平进行灌胃，剂量分别为2、5和10g/kg，空白对照组以0.1ml/10g的生理盐水灌胃，每日一次，连续7天。末次给药1小时后，将各对照组与实验组小鼠分别放入用纱布包有20g钠石灰的250ml广口瓶内，瓶口用凡士林涂抹盖严，以保持密闭不透气，以小鼠呼吸停止为指标，观察自小鼠放入瓶中起到小鼠死亡的时间，并记录。结果见表1。
表4不同剂量中药组合提取物对小鼠常压缺氧耐受时间的影响
| 组别 | 耐缺氧时间（min） |
| 空白组 | 26.64±2.47 |
| 实施例1 | 40.49±1.57* |
| 实施例2 | 42.88±2.07** |
| 实施例3 | 49.55±3.49** |
*与空白组比P＜0.05，**与空白组比＜0.01
由表4可见，中药组合提取物（实施例1实施例2实施例3）组小鼠常压耐缺氧时间与空白组相比有显著性的差异，这说明中药组合提取物能够延长小鼠常压耐缺氧耐受时间，该能力能够从侧面反映该组合提取物具有一定的抗疲劳能力。
Claims (3)
1.一种橄榄油复方保健喷雾剂，其特征在于是由以下药物按重量份数比制成的：
橄榄油25~45、蜂胶10~25、红景天油10~25、诺丽籽油10~25。
2.权利要求1所述的一种橄榄油复方保健喷雾剂的制备方法，包括以下步骤：
按比例称取上述原料；橄榄油、红景天油、诺丽籽油混合调配成调和油后，再与蜂胶制成油相混合物，再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂，即得。
3.权利要求1所述的橄榄油复方保健喷雾剂在提高免疫力、延缓衰老及降低血糖、血脂、血压的医用用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776585.0A CN105362417A (zh) | 2015-11-12 | 2015-11-12 | 一种橄榄油复方保健喷雾剂及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776585.0A CN105362417A (zh) | 2015-11-12 | 2015-11-12 | 一种橄榄油复方保健喷雾剂及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105362417A true CN105362417A (zh) | 2016-03-02 |
Family
ID=55365371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510776585.0A Pending CN105362417A (zh) | 2015-11-12 | 2015-11-12 | 一种橄榄油复方保健喷雾剂及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105362417A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982300A (zh) * | 2017-12-07 | 2018-05-04 | 青岛九远医疗科技有限公司 | 一种喷雾剂及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421232A (zh) * | 2002-12-13 | 2003-06-04 | 北京华源生命科贸发展有限公司 | 具有降血脂、延缓衰老功能的营养保健食品及其制备方法 |
| CN104987952A (zh) * | 2015-05-31 | 2015-10-21 | 陕西理工学院 | 从红景天全草中提取挥发油及红景天甙的方法 |
-
2015
- 2015-11-12 CN CN201510776585.0A patent/CN105362417A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421232A (zh) * | 2002-12-13 | 2003-06-04 | 北京华源生命科贸发展有限公司 | 具有降血脂、延缓衰老功能的营养保健食品及其制备方法 |
| CN104987952A (zh) * | 2015-05-31 | 2015-10-21 | 陕西理工学院 | 从红景天全草中提取挥发油及红景天甙的方法 |
Non-Patent Citations (1)
| Title |
|---|
| 郭志勇等，: "超临界萃取诺丽籽油工艺研究", 《现代食品科技》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982300A (zh) * | 2017-12-07 | 2018-05-04 | 青岛九远医疗科技有限公司 | 一种喷雾剂及其制备方法和应用 |
| CN107982300B (zh) * | 2017-12-07 | 2021-04-20 | 青岛九远医疗科技有限公司 | 一种喷雾剂及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104367765A (zh) | 一种用于治疗抑郁症的中药组合物及其制备方法和应用 | |
| CN102091315A (zh) | 生姜与乌梅组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
| CN105233010A (zh) | 一种补肾壮阳酒及其制备方法 | |
| CN106963820A (zh) | 胡椒属植物精油的用途 | |
| CN108785357A (zh) | 一种乳香酸与没药萜配伍组合物及其制备方法和应用 | |
| CN101284050B (zh) | 延胡索水溶性部位药物及制备方法和用途 | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN101081281A (zh) | 用于提高人体免疫力及抗疲劳的抵抗力胶囊及其制备方法 | |
| CN105796654B (zh) | 治疗腹泻型肠易激综合征中药组合物及脐贴及应用 | |
| CN105362417A (zh) | 一种橄榄油复方保健喷雾剂及制备方法 | |
| CN110624029A (zh) | 一种解郁宁心安神中药组合物及外用贴剂的制备方法 | |
| CN105477100A (zh) | 一种灵芝孢子油复方保健喷雾剂及制备方法 | |
| EP2508192B1 (en) | Agent for the treatment and prevention of diseases of the male urogenital system | |
| CN103083429B (zh) | 一种降血脂的中药组合物 | |
| CN109833381A (zh) | 一种改善睡眠的纯天然植物药组合物 | |
| CN102204676A (zh) | 一种抗睡眠剥夺应激损伤的食品 | |
| KR101511699B1 (ko) | 광천수가 함유된 아토피 피부염 개선용 조성물 | |
| CN103520302A (zh) | 一种沙棘叶抗疲劳胶囊及其制备方法 | |
| CN110384785B (zh) | 一种用于治疗病毒性感冒的外用中药药液及其制备方法 | |
| CN103710264B (zh) | 一种灵芝孢子的破壁辅助添加剂 | |
| Niranjan et al. | Pharmacological investigation of leaves of polypodium decumanum for antidiabetic activity | |
| CN102631397A (zh) | 一种改善脑部血液循环的中药组合物及其制备方法 | |
| CN105343465A (zh) | 一种韮菜籽油复方保健喷雾剂及制备方法 | |
| CN112791140A (zh) | 组合物及其在保护肝脏和降血脂中的用途 | |
| CN101664423A (zh) | 桂花降血脂有效部位及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160302 |
|
| RJ01 | Rejection of invention patent application after publication |